Drug-Loaded Tumor-Derived Microparticles Elicit CD8+ T Cell-Mediated Anti-Tumor Response in Hepatocellular Carcinoma
Yulin Chen,Yi Zhang,Jianjun Wang,Xiong Cai,Junzhang Chen,Xiaobo Min,Yunjie Xu,Qi Qin,Chidan Wan
DOI: https://doi.org/10.2147/ijn.s449694
IF: 7.033
2024-03-07
International Journal of Nanomedicine
Abstract:Yulin Chen, 1 Yi Zhang, 2 Jianjun Wang, 3 Xiong Cai, 1 Junzhang Chen, 1 Xiaobo Min, 1 Yunjie Xu, 1 Qi Qin, 1 Chidan Wan 1 1 Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 2 Hubei Engineering Research Center of Tumor-Targeted Biochemotherapy, Wuhan, 430030, People's Republic of China; 3 Department of Hepatobiliary Surgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, 621000, People's Republic of China Correspondence: Qi Qin; Chidan Wan, Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Wuhan, 430022, People's Republic of China, Email ; Background: Hepatocellular Carcinoma (HCC) poses significant challenges due to limited effective treatments and high recurrence rates. Immunotherapy, a promising approach, faces obstacles in HCC patients due to T-cell exhaustion and immunosuppression within the tumor microenvironment. Methods: Using doxorubicin-loaded tumor-derived microparticles (Dox-TMPs), the mice with H22 ascites model and subcutaneous tumors model were treated. Following the treatment, mice were re-challenged with H22 cells to compare the therapeutic effects and recurrence among different groups of mice, alongside examining the changes in the proportions of immune cells within the tumor microenvironment. Furthermore, Dox-TMPs were combined with anti-PD-1 to further validate their anti-tumor efficacy. In vitro studies using various liver cancer cell lines were conducted to verify the tumor-killing effects of Dox-TMPs. Additionally, CD8+ T cells from the abdominal cavity of tumor-free mice were co-cultured with H22 cells to confirm their specific tumor-killing abilities. Results: Dox-TMPs demonstrate effective anti-tumor effects both in vitro and in vivo. In vivo, their effectiveness primarily involves enhancing CD8+ T cell infiltration, alleviating T cell immunosuppression, and improving the immune microenvironment to combat tumors. When used in combination with anti-PD-1, their anti-tumor effects are further enhanced. Moreover, some mice treated with Dox-TMPs developed anti-tumor immunity, displaying a self-specific T-cell immune response upon re-challenged with tumor cells. This suggests that Dox-TMPs also have the potential to act as a long-term immune response against tumor recurrence, indicating their capability as a tumor vaccine. Conclusion: Dox-TMPs exhibit a dual role in liver cancer by regulating T cells within the tumor microenvironment, functioning both as an anti-tumor agent and a potential tumor vaccine. Keywords: liver cancer, drug-loaded microparticles, tumor immune microenvironment, tumor vaccine Graphical Primary liver cancer is the sixth most common cancer worldwide and stands as the third leading cause of cancer-related deaths. 1 HCC constitutes the predominant type of primary liver cancer, accounting for 75–86% of cases. 2 Despite the development of effective strategies such as radiotherapy, chemotherapy, and liver transplantation in recent years, surgical resection remains the primary treatment method for early-stage patients. Unfortunately, the 5-year survival rate for primary liver cancer remains relatively low, with significant contributing factors being tumor recurrence and metastasis. 3,4 The recurrence rate for malignant primary liver tumors reaches as high as 70%, with the majority of these recurrences occurring within the first 1–3 years following clinical resection. 5 Currently, there is no widely accepted effective neoadjuvant or adjuvant chemotherapy regimen to reduce the risk of the recurrence. 5 Systemic chemotherapy and chemoembolization have shown little effectiveness, and sorafenib has not been successful in preventing recurrence after early HCC resection or ablation. 6 Other drugs, such as retinoids, vitamin K2, transarterial 131I-lipiodol, and interferon, have shown only preliminary positive results. 7 While liver transplantation is the most effective option, it is unable to fully meet clinical needs due to donor scarcity and indication issues. 5 Therefore, developing effective methods to prevent HCC recurrence is an urgent current need. The tumor immune microenvironment (TME) plays a pivotal role in HCC progression and recurrence. In particular, the presence and function of CD8+ T cells, a subset of cytotoxic T lymphocytes, are critical in mounting an effective antitumor response. -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology